ProKidney

Historical price data

ProKidney's mission is to transform the treatment of chronic kidney disease by developing rilparencel, a novel autologous cell therapy designed to preserve kidney function and delay or prevent the need for dialysis or transplant. The company's key achievement is advancing this therapy into a pivotal Phase 3 clinical study (PROACT 1/REGEN-006), supported by RMAT designation and promising Phase 2 data. Its strategy leverages a proprietary, scalable manufacturing platform for a personalized therapy that avoids the need for chronic immunosuppression, targeting a large, underserved patient population with significant commercial potential.

Proprietary Renal Autologous Cell Therapy (RACT/REACT) platform that harvests, expands, and reinfuses a patient's own kidney cells via renal artery infusion to promote tissue repair and preserve function, eliminating the need for immunosuppression.

ProKidney's primary competition comes from standard-of-care pharmaceuticals (SGLT2i, GLP-1 RAs) that slow but do not halt progression, and earlier-stage regenerative approaches (allogeneic MSCs). Its key advantages are its late-stage lead, autologous platform avoiding immunosuppression, and focus on a broad, high-need advanced CKD population where no regenerative therapies exist.